Long-term lecanemab data show increased patient benefit with maintained safety profile
Go back to Long-term lecanemab data show increased patient benefit with maintained safety profile| BARNES GROUP, Inc. (NYSE: B) | Delayed: 40.83 -0.23 (0.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $41.06 | 52 Week High | $44.27 | |||
| Open | $40.68 | 52 Week Low | $30.07 | |||
| Day High | $40.98 | P/E | 31.17 | |||
| Day Low | $40.59 | EPS | $1.31 | |||
| Volume | 2,875,863 | |||||
| BIOAMBER, Inc. (NASDAQ: BIOA) | Delayed: 5.94 -0.4 (6.31%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.34 | 52 Week High | $8.73 | |||
| Open | $6.24 | 52 Week Low | $2.86 | |||
| Day High | $6.30 | P/E | N/A | |||
| Day Low | $5.88 | EPS | $-3.82 | |||
| Volume | 482,162 | |||||



